Trial Profile
A study of tazemetostat in combination with a B-cell signaling agent or other emerging targeted therapies for B-cell lymphomas
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2015
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary) ; Antineoplastics
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 28 Dec 2015 According to an Epizyme media release, this trial is expected to start in the first half of 2016.
- 23 Jun 2015 New trial record